在可切除的状黑色素瘤中,新辅助性瘤病毒orienx010和toripalimab:一项Ib期试验
Jiayong Liu1, Xuan Wang2, Zhongwu Li3
1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Bone and Soft Tissue Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
Signal transduction and targeted therapy
|November 21, 2024
概括
新辅助性瘤性病毒 (ori) 与抗PD-1 (tori) 结合,在状黑色素瘤 (AM) 中显示出有前途的疗效. 这种疗法实现了高响应率和优异的2年无复发生存率,并具有可管理的副作用.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 黑色素瘤研究 黑色素瘤研究
背景情况:
- 新辅助性PD-1抑制剂在皮肤黑色素瘤中表现有前途.
- 在状黑色素瘤 (AM) 中新辅助疗法的有效性在很大程度上是未知的.
- 与皮肤黑色素瘤相比,状黑色素瘤具有明显的生物学特征.
研究的目的:
- 评估新辅助性瘤病毒 (ori) 与抗PD-1 (toripalimab) 结合在可切除的状黑色素瘤中的疗效和安全性.
- 为了评估放射和病理反应率.
- 为了确定无复发生存率 (RFS) 和无事件生存率 (EFS).
主要方法:
- Ib期试验 (NCT04197882) 涉及30名患有III/IV期切除性AM的患者.
- 在手术前12周使用ori和toripalimab进行新辅助治疗.
- 手术后1年的辅助托里帕利马布治疗,随访时间中位数为35.7个月.
主要成果:
- 放射和病理学反应率分别为36.7%和77.8%.
- 完整的病理反应率为14.8%.
- 两年的RFS和EFS利率分别为81.5%和73%. 所有患者都经历了不良事件,主要是1-2级.
结论:
- 型病毒和toripalimab的新辅助组合疗法在状黑色素瘤中表现出显著的抗瘤活性.
- 治疗方案提供高响应率和有利的长期生存结果.
- 需要进一步研究免疫调节效应,包括三级淋巴体结构和细胞因子概况.
相关概念视频
01:27Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K